Fachbereich Veterinärmedizin



    Effective treatment of respiratory alphaherpesvirus infection using RNA interference (2009)

    Zeitschriftenartikel / wissenschaftlicher Beitrag
    Fulton, Amy
    Peters, Sarah T
    Perkins, Gillian A
    Jarosinski, Keith W
    Damiani, Armando
    Brosnahan, Margaret
    Buckles, Elizabeth L
    Osterrieder, Nikolaus
    Van de Walle, Gerlinde R
    PLoS one; 4(1) — S. e4118
    ISSN: 1932-6203
    DOI: 10.1371/journal.pone.0004118
    Pubmed: 19122813
    Institut für Virologie

    Robert-von-Ostertag-Str. 7-13
    Gebäude 35
    14163 Berlin
    +49 30 838 51833

    Abstract / Zusammenfassung

    Equine herpesvirus type 1 (EHV-1), a member of the Alphaherpesvirinae, is spread via nasal secretions and causes respiratory disease, neurological disorders and abortions. The virus is a significant equine pathogen, but current EHV-1 vaccines are only partially protective and effective metaphylactic and therapeutic agents are not available. Small interfering RNAs (siRNA's), delivered intranasally, could prove a valuable alternative for infection control. siRNA's against two essential EHV-1 genes, encoding the viral helicase (Ori) and glycoprotein B, were evaluated for their potential to decrease EHV-1 infection in a mouse model. METHODOLOGY/PRINCIPAL FNDINGS: siRNA therapy in vitro significantly reduced virus production and plaque size. Viral titers were reduced 80-fold with 37.5 pmol of a single siRNA or with as little as 6.25 pmol of each siRNA when used in combination. siRNA therapy in vivo significantly reduced viral replication and clinical signs. Intranasal treatment did not require a transport vehicle and proved effective when given up to 12 h before or after infection.

    siRNA treatment has potential for both prevention and early treatment of EHV-1 infections.